# NextRNA Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nextrna-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.nextrnatx.com
- Total disclosed funding: $23M
- Latest round: Series A (Jan 12, 2022)
- Investors on record: 7

## About

Based in Massachusetts, US, and founded in 2019, NextRNA Therapeutics, Inc., aka NextRNA operates as a biotechnology company that focuses on the development of RNA-targeted transformative therapies for patients with pathogenic diseases. The company was co-founded by Dominique Verhelle (CSO and interim CEO), Julia A Novina, Marc Cohen, and Leon Wert-Lamas, and in March 2022, NextRNA Therapeutics, Inc. raised USD 46.8 million in series A funding co-led by new investors Cobro Ventures and Lightchain Capital, with participation from other new investors.

The company develops small-molecule therapies that target human cells' non-coding RNAs, or ncRNAs (RNA molecules that are not converted into proteins), which are responsible for causing pathogenic disorders through interaction with normal protein cells. The company's medicines limit ncRNA interactions with proteins and prevent dangerous protein mutations, resulting in the treatment of a variety of diseases in the fields of neurology, oncology, and immunology.

The company intends to use the March 2022 funding to expand its target and drug discovery engine, and product pipeline.

## Funding rounds

- Series A, Jan 12, 2022, $23M — Jefferies, Circle Squared, Rivas Capital, Cobro Ventures, Willett Advisors LLC, Lightchain Capital, Evans Capital

## Investors

- Jefferies (https://capitalatlas.ai/funds/jefferies) — Series A
- Circle Squared — Series A
- Rivas Capital — Series A
- Cobro Ventures (https://capitalatlas.ai/funds/cobro-ventures) — Series A
- Willett Advisors LLC — Series A
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Series A
- Evans Capital (https://capitalatlas.ai/funds/evans-capital) — Series A